极早产儿视网膜病变:微早产与纳米早产婴儿的疾病负担、治疗方式与视觉结局
该回顾性单中心临床队列研究纳入2013至2023年符合微早产(胎龄24-26周和/或出生体重600-799克)或纳米早产(胎龄<24周和/或出生体重<600克)标准的婴儿,共702例纳入、525例分析。视网膜病变见于891眼(84.9%),225眼(21.4%)发生1型病变需激光和/或抗VEGF治疗,74例132眼(12.6%)需再治疗。纳米早产儿病变更重、更偏后极部、治疗年龄更早、各治疗方式使用率更高、弱视更多、最终视力更差、发育迟缓更常见。
要点
- 低胎龄、低出生体重和中枢神经系统出血性损伤与需治疗的视网膜病变相关。
- 纳米早产儿较微早产儿病变更严重、弱视率更高、最终视力更差。
- 尽管治疗可稳定病变,患儿仍面临视觉和发育并发症的持续挑战。
核心结论
- 治疗可稳定病变,但患儿仍面临视觉和发育并发症的持续挑战。
- 低胎龄、低出生体重和中枢神经系统损伤是需治疗视网膜病变的重要危险因素。
- 纳米早产儿较微早产儿有更高的更严重视网膜病变率、弱视率和更差的视觉结局。
- 这些发现强调对该人群进行筛查和随访的重要性,并为眼科医生提供了有价值的自然病史、治疗和结局信息。
研究设计与样本
- 回顾性、单中心临床队列研究,纳入2013至2023年符合微早产(胎龄24-26周和/或出生体重600-799克)或纳米早产(胎龄<24周和/或出生体重<600克)标准的婴儿。
- 共筛查3239例婴儿,702例纳入,排除失访后525例纳入分析。
主要发现
- 视网膜病变见于891眼(84.9%)。
- 225眼(21.4%)发生1型病变,需激光和/或抗VEGF治疗。
- 74例患者共132眼(12.6%)需再治疗。
- 多变量回归显示低胎龄、低出生体重和中枢神经系统出血性损伤与需治疗的视网膜病变相关。
- 纳米早产儿较微早产儿表现更严重的视网膜病变、更偏后极部的病变、更早年龄接受治疗的比例更高、所有治疗方式的使用率更高、弱视发生率更高、最终视力更差、发育迟缓更常见。
临床怎么用
- 原文结论强调对该人群进行筛查和随访的重要性,并为眼科医生提供了自然病史、治疗和结局信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the treatment and outcomes of retinopathy of prematurity (ROP) in high-risk extremely premature infants. DESIGN: Retrospective, single-center clinical cohort study. METHODS: Infants meeting criteria for micro-prematurity (24-26 weeks gestational age [GA] and/or birth weight [BW] 600-799 grams) or nano-prematurity (<24 weeks GA and/or BW <600 grams) from 2013 to 2023 were included. RESULTS: Total 3239 infants were screened, of which 702 infants were included and 525 infants were selected for analysis after excluding patients lost to follow-up ROP was observed 891 eyes (84.9%)225 eyes (21.4%) developed type 1 disease and required treatment. with laser and/or anti-VEGF. One hundred and thirty two eyes of 74 patients (12.6%) required re-treatment. Lower GA, lower BW, and central nervous system hemorrhagic injury were associated with treatment-warranted ROP on multivariable regression. The nano-premature demonstrated more severe ROP, more posterior disease, higher rates of treatment at earlier ages, increased incidence of treatment by all modalities, higher rates of amblyopia, worse final visual acuity, and more frequent developmental delay. CONCLUSION: While treatment can stabilize the disease, patients face ongoing challenges, including visual and developmental complications. Lower GA, lower BW, and central nervous system injury emerged as significant risk factors for treatment-warranted ROP. Nano-premature infants showed higher rates of more severe ROP, amblyopia, and poorer visual outcomes compared to micro-premature infants. These findings highlight the importance of screening and follow-up in this population and provide valuable natural history, treatment, and outcome information for ophthalmologists caring for these high-risk infants.
引用
- Yuan M, Chaaya C, Altamirano F, et al. Retinopathy of Prematurity in the Extremely Premature: Disease Burden, Treatment Approaches, and Visual Outcomes in Micro- and Nano-Premature Infants. Am J Ophthalmol. 2025. PMID: 40796026. doi:10.1016/j.ajo.2025.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。